Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

NCT05568680 is registered in ClinicalTrials.gov with Verismo Therapeutics as lead sponsor.

NCT NCT05568680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05568680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Lead sponsor
Verismo Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
March 30, 2023
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma recurrent, mesothelioma, malignant, ovarian cancer